Camlin Fine Sciences Limited

As of June 30, 2026, Camlin Fine Sciences Limited carries a market capitalization of 25.62B, placing it among publicly traded companies globally. Its enterprise value stands at 25.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Camlin Fine Sciences Limited's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Camlin Fine Sciences Limited has 192.10M shares outstanding.

As of June 30, 2026, Camlin Fine Sciences Limited trades at a trailing price-to-earnings ratio of 431.30.

As of June 30, 2026, Camlin Fine Sciences Limited trades at an EV/EBITDA multiple of 14.59 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 25.62B versus a market cap of 25.62B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 12.43M in revenue per employee across its workforce of 1,498.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Camlin Fine Sciences Limited recorded an income tax benefit of -7.42M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -654.68M and 58.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Camlin Fine Sciences Limited's stock has declined approximately 55.86% over the past 52 weeks. The 50-day moving average sits at 99.55, while the 200-day moving average is 123.98.

Over the twelve months ended June 30, 2026, Camlin Fine Sciences Limited generated 18.62B in revenue and converted that into 58.82M in net income, yielding earnings per share of -3.39. EBITDA reached 1.76B, while operating income came in at 1.37B.

Over the twelve months ended June 30, 2026, Camlin Fine Sciences Limited posted a gross margin of 45.25, reflecting its pricing power and cost economics. The operating margin of 7.34 and net profit margin of 0.32 provide insight into operational efficiency.

Camlin Fine Sciences Limited's most recent stock split took place on January 8, 2025 with a 127:130 split ratio.